GlassScriptPhysician profile
Tolga Erim
NPI 1689636524
$26,292.27
in general payments reported to CMS, 2019-2025
26 companies · $2,739 in 2025
The $2,739 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $155 · 2021: $233 · 2022: $1,687 · 2023: $717 · 2024: $6,915 · 2025: $2,739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,500 · Food and Beverage: $3,882 · Travel and Lodging: $989.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,500.00 |
| Food and Beverage | $3,881.97 |
| Travel and Lodging | $989.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $15,322.16 | 2019-2025 | General - Endochoice, Autotome Rx 49, Spyglass |
| Neptune Medical INC. | $5,500.00 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,433.47 | 2022-2024 | Xifaxan |
| Abbvie INC. | $968.37 | 2019-2025 | |
| Medtronic, INC. | $889.36 | 2022-2025 | Endoflip, Nexpowder, Signet |
| Madrigal Pharmaceuticals | $455.10 | 2024-2025 | Rezdiffra, Resmetirom |
| Micro-Tech Endoscopy USA, INC. | $411.58 | 2024-2025 | Eyemax |
| Phathom Pharmaceuticals, INC. | $153.83 | 2024-2025 | Voquezna |
| Genzyme Corporation | $146.81 | 2024 | |
| Lumendi LLC | $130.75 | 2019 | |
| Gilead Sciences, INC. | $125.00 | 2019 | |
| Covidien LP | $123.20 | 2019 | |
| Intuitive Surgical, INC. | $109.67 | 2023 | Da Vinci Surgical System |
| Cardiva Medical, INC. | $101.71 | 2021 | |
| Merck Sharp & Dohme LLC | $83.59 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endogastric Solutions, INC | $70.23 | 2023 | Esophyx |
| Steris Corporation | $54.18 | 2025 | |
| Aimmune Therapeutics, INC. | $47.29 | 2025 | Zenpep |
| Qol Medical, LLC | $36.78 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.46 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $20.00 | 2022 | |
| Ardelyx, INC. | $18.78 | 2024 | Ibsrela |
| Apollo Endosurgery US INC | $18.69 | 2022 | |
| Coloplast Corp | $17.74 | 2025 | |
| Janssen Biotech, INC. | $16.32 | 2025 | Tremfya |
| Celgene Corporation | $16.20 | 2024 | Zeposia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tolga Erim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.